Megan Lyle

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers et al. · The Lancet Oncology · 2021 · 201 citations

Oncology, Anti-pd-1 Therapy, Melanoma +10

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

Samantha Bowyer, Aparna D. Rao, Megan Lyle et al. · Melanoma Research · 2014 · 77 citations

Oncology, Medicine, Braf K601e +12

The nature and management of metastatic melanoma after progression on <scp>BRAF</scp> inhibitors: Effects of extended <scp>BRAF</scp> inhibition

Matthew Chan, Lauren E. Haydu, Alexander M. Menzies et al. · Cancer · 2014 · 72 citations

Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with <scp>BRAF</scp> or combined <scp>BRAF</scp> and MEK inhibitors

Alexander M. Menzies, James S. Wilmott, Martin Drummond et al. · Cancer · 2015 · 49 citations · Full text

Metastasis‐specific patterns of response and progression with anti‐<scp>PD</scp>‐1 treatment in metastatic melanoma

Jenny Lee, Megan Lyle, Alexander M. Menzies et al. · Pigment Cell & Melanoma Research · 2017 · 44 citations